Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Laureano, Raquel S; Sprooten, Jenny; Vanmeerbeerk, Isaure; Borràs, Daniel; Govaerts, Jannes; Naulaerts, Stefan; Berneman, Zwi; Beuselinck, Benoît; Bol, Kalijn F.; Borst, Jannie; Coosemans, An; Datsi, Angeliki; Fučíková, Jitka; Kinget, Lisa; Neyns, Bart; Schreibelt, Gerty; Smits, Evelien; Sorg, Rüdiger V.; Špíšek, Radek; Thielemans, Kris; Tuyaerts, Sandra; Vleeschouwer, Steven De; Vries, I. Jolanda M. de; Xiao, Yanling; Garg, Abhishek D.

doi:10.1080/2162402x.2022.2096363

Cited by 74 publications

(63 citation statements)

References 288 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, more than 400 clinical trials of DC vaccines have been registered on in different cancers (accessed on 15 August 2022). Results of completed studies highlight that DC vaccines are relatively safe and result in positive patient outcomes, although in only a minority of patients [ 30 , 31 , 32 , 33 ]. Consequently, in 2010, the FDA approved the first DC vaccine (Sipuleucel-T) against metastatic prostate cancer [ 30 , 34 ].…”

Section: Immunotherapies In Ocmentioning

confidence: 99%

Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer

Audhut

Deschoemaeker

Allonsius

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Ovarian cancer (OC) is the deadliest gynecological malignancy in developed countries and is the seventh-highest cause of death in women diagnosed with cancer worldwide. Currently, several therapies are in use against OC, including debulking surgery, chemotherapy, as well as targeted therapies. Even though the current standard-of-care therapies improve survival, a vast majority of OC patients relapse. Additionally, immunotherapies have only resulted in meager patient outcomes, potentially owing to the intricate immunosuppressive nexus within the tumor microenvironment. In this scenario, dendritic cell (DC) vaccination could serve as a potential addition to the therapeutic options available against OC. In this review, we provide an overview of current therapies in OC, focusing on immunotherapies. Next, we highlight the potential of using DC vaccines in OC by underscoring the different DC subsets and their functions in OC. Finally, we provide an overview of the advances and pitfalls of current DC vaccine strategies in OC while providing future perspectives that could improve patient outcomes.

show abstract

Section: Immunotherapies In Ocmentioning

confidence: 99%

Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer

Audhut

Deschoemaeker

Allonsius

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…The disappointment from the early “DC era” is presumably due to the fact that many studies were not designed in combination with other immunotherapeutic interventions and patients were enrolled at late stages of the disease, often associated with advanced tumor microenvironment and the disease-elicited immune system defects [ 143 , 144 , 145 ]. However, DC-based immunotherapy still goes on through efforts to find new ways for their improvement [ 146 ]. Due to advances in genomics, many recent DC-based approaches focus on targeting neoantigens that have become considered powerful targets for cancer immunotherapy [ 147 , 148 , 149 ], including DC-based vaccines [ 150 ].…”

Section: Dcs In Immunotherapy Of Solid Tumorsmentioning

confidence: 99%

“…Three decades ago, DCs were thought to be highly promising immune cells for cancer therapy, namely, for ACT-based immunotherapy. Despite many disappointments in clinical trials, the use of these cells still showed a notable therapeutic efficacy, and their role in cancer immunotherapy is indeed still ongoing [ 146 , 154 , 155 ]. As research into immunotherapy accelerated after the immune checkpoint inhibitor had entered the field, the efficacy of DC-based immunotherapy was found to be largely restricted by the settings (immunotype) of the patient’s tumor immune microenvironment [ 153 , 156 ].…”

Section: Mc/dc Interplay As the Cellular Immune Checkpoint For Cancer...mentioning

confidence: 99%

“…Moreover, there is growing evidence that the functional heterogeneity of DC populations is even more complex than previously thought [ 73 ], and, therefore, more attention needs to be paid to the way DCs are ex vivo produced for ACT [ 82 ]. This attention relates to the DC differentiation process, antigen loading strategy, and DC maturation [ 82 , 146 ]. In this regard, the interaction of MCs with DCs may come with an advantage in the ex vivo preparation of DCs.…”

Section: Mc/dc Interplay As the Cellular Immune Checkpoint For Cancer...mentioning

confidence: 99%

See 1 more Smart Citation

Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors

Kalkusova

Smite

Darras

et al. 2022

IJMS

View full text Add to dashboard Cite

The immune checkpoint inhibitors have revolutionized cancer immunotherapy. These inhibitors are game changers in many cancers and for many patients, sometimes show unprecedented therapeutic efficacy. However, their therapeutic efficacy is largely limited in many solid tumors where the tumor-controlled immune microenvironment prevents the immune system from efficiently reaching, recognizing, and eliminating cancer cells. The tumor immune microenvironment is largely orchestrated by immune cells through which tumors gain resistance against the immune system. Among these cells are mast cells and dendritic cells. Both cell types possess enormous capabilities to shape the immune microenvironment. These capabilities stage these cells as cellular checkpoints in the immune microenvironment. Regaining control over these cells in the tumor microenvironment can open new avenues for breaking the resistance of solid tumors to immunotherapy. In this review, we will discuss mast cells and dendritic cells in the context of solid tumors and how these immune cells can, alone or in cooperation, modulate the solid tumor resistance to the immune system. We will also discuss how this modulation could be used in novel immunotherapeutic modalities to weaken the solid tumor resistance to the immune system. This weakening could then help other immunotherapeutic modalities engage against these tumors more efficiently.

show abstract

“…In case of infections, such target cells predominantly consist of cells against which pathogenic microbes show specific tropism (e.g., epithelial, or immune cells) [ 7 ], or cells that die during host level-responses against the infection (e.g., neutrophils, macrophages, or T cells) [ 8 ]. In case of cancer, such target cells predominantly consist of cancer cells unable to cope with genetic instability or TME-associated stressors (e.g., hypoxia, acidosis, or nutrient-deprivation), followed by immune cells that die due to TME-associated stressors (e.g., neutrophils, dendritic cells) or cancer-driven direct induction of dysfunction or exhaustion (e.g., CD8 + T cells) [ 6 , 9 , 10 ]. Such cell death induced due to the progression of infection or a tumour, largely supports rather than suppress, the severity of disease and patient mortality [ 11 ].…”

mentioning

confidence: 99%